Search research articles
Contact Us
Filters
Showing results (111-120 of 182) with videos related to
Page
of 19
Sort By:
The Oncologist
|
September 28, 2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study
Johanna C Bendell, Tanios S Bekaii-Saab, Allen L Cohn, et al.
Investigational New Drugs
|
June 12, 2014
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
James M Cleary, Caio Max S Rocha Lima, Herbert I Hurwitz, et al.
The Oncologist
|
July 29, 2011
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
Ivy Altomare, Johanna C Bendell, Karen E Bullock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2005
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
Adrian M Jubb, Herbert I Hurwitz, Wei Bai, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society
|
July 9, 2003
A clinical model of dermal wound angiogenesis
A Craig Lockhart, Rod D Braun, Daohai Yu, et al.
Cancer Chemotherapy and Pharmacology
|
July 12, 2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
Robert E Martell, Bercedis L Peterson, Harvey Jay Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies
L Ochoa, H I Hurwitz, G Wilding, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 23, 2008
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma
John W Nelson, A Paiman Ghafoori, Christopher G Willett, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 15, 2007
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results
Brian G Czito, Johanna C Bendell, Christopher G Willett, et al.
Cancer Investigation
|
October 21, 2011
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer
Nan Soon Wong, Kellen L Meadows, Lee S Rosen, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 182) with videos related to
Sort By:
Page
of 19
The Oncologist
|
September 28, 2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study
Johanna C Bendell, Tanios S Bekaii-Saab, Allen L Cohn, et al.
Investigational New Drugs
|
June 12, 2014
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
James M Cleary, Caio Max S Rocha Lima, Herbert I Hurwitz, et al.
The Oncologist
|
July 29, 2011
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
Ivy Altomare, Johanna C Bendell, Karen E Bullock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2005
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
Adrian M Jubb, Herbert I Hurwitz, Wei Bai, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society
|
July 9, 2003
A clinical model of dermal wound angiogenesis
A Craig Lockhart, Rod D Braun, Daohai Yu, et al.
Cancer Chemotherapy and Pharmacology
|
July 12, 2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
Robert E Martell, Bercedis L Peterson, Harvey Jay Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies
L Ochoa, H I Hurwitz, G Wilding, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 23, 2008
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma
John W Nelson, A Paiman Ghafoori, Christopher G Willett, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 15, 2007
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results
Brian G Czito, Johanna C Bendell, Christopher G Willett, et al.
Cancer Investigation
|
October 21, 2011
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer
Nan Soon Wong, Kellen L Meadows, Lee S Rosen, et al.
Page
of 19